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Abstract
Brain-specific homing and direct interactions with the neural substance are prominent hypotheses for brain metastasis
formation and a modern manifestation of Paget’s ‘‘seed and soil’’ concept. However, there is little direct evidence for this
‘‘neurotropic’’ growth in vivo. In contrast, many experimental studies have anecdotally noted the propensity of metastatic
cells to grow along the exterior of pre-existing vessels of the CNS, a process termed vascular cooption. These observations
suggest the ‘‘soil’’ for malignant cells in the CNS may well be vascular, rather than neuronal. We used in vivo experimental
models of brain metastasis and analysis of human clinical specimens to test this hypothesis. Indeed, over 95% of early
micrometastases examined demonstrated vascular cooption with little evidence for isolated neurotropic growth. This vessel
interaction was adhesive in nature implicating the vascular basement membrane (VBM) as the active substrate for tumor cell
growth in the brain. Accordingly, VBM promoted adhesion and invasion of malignant cells and was sufficient for tumor
growth prior to any evidence of angiogenesis. Blockade or loss of the b1 integrin subunit in tumor cells prevented adhesion
to VBM and attenuated metastasis establishment and growth in vivo. Our data establishes a new understanding of CNS
metastasis formation and identifies the neurovasculature as the critical partner for such growth. Further, we have elucidated
the mechanism of vascular cooption for the first time. These findings may help inform the design of effective molecular
therapies for patients with fatal CNS malignancies.
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Introduction
Brain metastases are the most common malignant tumors of the
central nervous system (CNS) outnumbering primary brain tumors
such as glioblastoma in prevalence by tenfold [American Cancer
Society, http://www.cancer.org/]. Over 20% of all cancer
patients develop metastatic disease to the CNS and have a 9
month median survival with maximal treatment [1–4]. As modern
therapies allow improved peripheral control of primary and
metastatic disease, such as trastuzumab for metastatic breast
cancer, the incidence of brain metastasis appears to be
paradoxically increasing [4–7]. This may be due to several reasons
including the blood-brain barrier preventing drug entry, tumor
dormancy, positive selection of ‘‘brain-seeking’’ or therapy-
resistant subclones, or iatrogenic induction of new functional
mutations. Hence, further characterization of these mechanisms
and identification of new strategies for treatment of brain
metastasis are important goals.
Clinically, brain metastases most commonly arise from lung,
breast, and melano-carcinomas. The major requirements for
metastasis to distant sites appear to vary by organ and remain
incompletely understood [8–11]. The pathophysiology of brain
metastasis, in particular, remains elusive. In metastasis to lung and
bone, characteristic patterns of gene expression in MDA-MB-231-
derived mammary carcinoma cells have been shown to enable
organ specific colonization [10]. Such factors have not yet been
identified for brain metastasis, but are likely to exist as mouse and
human carcinoma lines have been selected for increased brain
colonization [11,12]. However, these characterizations of the
‘‘seed’’ largely neglect contributions from the ‘‘soil’’ and appear to
be cell line specific [13]. On the other hand, there is a persistent
assumption in the literature that brain metastasis is the result of
specific interactions with the neural elements of the brain
parenchyma mediating ‘‘brain homing’’ (or targeted metastasis to
the brain), direct cell attachment and establishment, invasion, and
progressive growth into micro- and macrometastases [1,5,14,15].
These ideas are certainly consistent with the classic concept of
Pagetian ‘‘soil’’, however, there currently exist no in vivo data to
support such statements and indeed very few studies address these
topics directly. In contrast, we have noted many experimental brain
metastasis studies dating back several decades have anecdotally
describedearlygrowthoftumorcellsalongpre-existingbrainvessels
([16–22]; Table S1). This relationship is reminiscent of vascular
cooption described in a rat glioma model [23]. These findings
suggest the neural elements of the brain parenchyma do not provide
a sufficient substrate for metastatic carcinoma growth and instead
implicates the existing neurovasculature as a key niche for
malignant progression. This also supports the data by Fidler and
colleagues [24] that suggests sprouting neoangiogenesis may not be
necessary for the initiation of metastasis growth in the brain.
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human pathological specimens to analyze the temporospatial
growth pattern of brain metastasis microcolonies in order to
characterize the relationship between metastatic tumor cells and
the existing neurovasculature. We focused on timepoints as early
as 3d after intravascular injection in order to focus on the earliest
events in microcolony formation. We found that brain microme-
tastases in mouse and human tissue utilized vascular cooption for
growth rather than invading and growing within the neural
parenchyma. Vascular cooption can be an alternative to neo-
angiogenesis and likely acts to deliver blood borne nutrients and
oxygen. We propose here that vascular cooption has an additional
function for brain metastases; interactions with the pre-existing
vessels are required for initial adhesion, proliferation, invasion,
and microcolony establishment. We show that the neural
parenchyma of the brain cannot substitute in supplying these
functions. This work identifies the central role of the vasculature
for metastatic growth in the CNS as well as providing insight into
the mechanism of adhesive vascular cooption. These novel
concepts may allow the development of more effective therapies
for brain metastasis.
Results
Perivascular growth of early brain micrometastases in
vivo
To characterize the vascular association of tumor cells in
experimental brain metastasis models, we examined early brain
microcolony formation after intracardiac injection of metastatic
mouse and human tumor cells. It has been anecdotally noted that
microcolonies in experimental brain metastasis assays often tended
to grow along preexisting vessels (Table S1). We established that
this pattern occurs with a high frequency and across all cell lines
we tested. 4T1-GFP mammary carcinoma cells [25] were found to
be intimately associated with the perivascular surface of brain
microvessels from the earliest timepoint at 3 d up to 14 d (Fig. 1A)
after injection into syngeneic BALB/c mice. This was observed in
over 97% of the microcolonies at all timepoints (Fig. 1B). Similar
vascular associations resulted from the intracardiac injection of the
human breast carcinoma cell lines MDA-MB-231 and its ‘‘brain
seeking’’ variant cell line MDA231BR [11], the human melano-
carcinoma cell line A7 in SCID mice, and the murine melanoma
cell line K1735M2 injected into syngeneic C3H/He mice. Brain
microcolonies from each of these cell lines examined between 7
and 14 d after injection were associated with vessels in the same
pattern consistent with vascular cooption (Fig. 1C). Interestingly,
the ‘‘brain seeking’’ MDA231BR line showed equivalent vascular
association and microcolony area as the parental line, although the
number of colonies produced by injection of the parental cells was
approximately 2 fold less (Fig. S1). Thus perivascular colony
formation was the predominant pattern of growth by carcinoma
cells in experimental in vivo metastasis assays.
We verified that the colonies resulted from proliferation of
vascular-associated tumor cells between 3 and 7 d by measuring
tumor area (Fig. 1D) and with BrdU immunohistochemistry
(Fig. 1E). Similar to prior studies [16,24,26], these microcolonies
appeared to rely on pre-existing vessels for growth. First,
proliferation of tumor cells was observed within 1 week of
injection and prior to any evidence of neoangiogenesis (Figs. 1D
and 1E). Second, vessel morphology appeared largely normal,
however, vessel density was significantly lower in tumor-involved
areas of the brain (Fig. S2). Third, despite the extensive
perivascular involvement of the tumors, the endothelial blood
brain barrier (BBB) markers GLUT-1 (Fig. 1F and S2) and ZO-1
(not shown) remained unaltered. We verified BBB integrity with
static and dynamic studies of function including gadolinium-
enhanced MRI (Fig. S2), small molecular weight TRITC-dextran
injection (not shown), and tyramide-signal amplification enhanced
immunohistochemistry for IgG extravasation (Fig. S2) at time-
points up to 14 d. These results demonstrated that early brain
micrometastasis formation was associated with minimal neoangio-
genesis leading to the conclusion that growth must be dependent
upon pre-existing vessels. Finally, to verify the perivascular
preference of brain micrometastases was not biased by intravas-
cular delivery of tumor cells, we characterized a syngeneic model
of spontaneous brain metastasis [27]. Brain sections were
examined for spontaneous micrometastases 5–7 weeks after
orthotopic injection of 4T1-GFP cells into the mammary fat pad
(n=10 mice). The growth and morphological characteristics of
these colonies were indistinguishable from those derived from
intracardiac delivery of cells demonstrating both intact GLUT-1-
positive vasculature and angiotropic spread upon adjacent
capillaries (Fig. 1F).
To assess the clinical relevance of frequent vascular cooption in
experimental metastasis, we asked whether tumor cells within
human brain metastasis specimens displayed a similar vascular
association. In brain micrometastases and tumors with carcino-
matous CNS spread that could be considered at the early stages of
parenchymal colonization, the patterns were similar to those in the
experimental models above, with the tumor cells in these brain
metastases appearing to track along the blood vessels (Fig. 2A).
Quantitation of vascular cooption in these cases from primary
tumors of varied origin revealed that 98.2% of metastatic brain
colonies were vascular-associated (Fig. 2B and Table 1). Based on
clinical pathologic indices, there was little clear morphological
evidence characteristic of tumor angiogenesis in these cases
(Table 1 and Fig. 2A). Therefore, early growth of brain metastasis
microcolonies in experimental models and human clinical
specimens occurs via intimate interactions with the existing
neurovasculature. This growth can occur immediately after
extravasation (as early as 3 d after intra-arterial injection) and
does not require neovascularization.
Vascular cooption after intraparenchymal injection
We further asked whether the association of tumor cells with the
vessels was merely a matter of location after extravasation. This
was tested by injecting tumor cells directly into the brain allowing
equivalent access to both the vascular and the neural elements of
the brain. 4T1-GFP cells after intraparenchymal injection formed
colonies surrounding vessels within 2 days (Fig. 3A). 93% of tumor
profiles were vascular-associated at 4 d (4T1-GFP cells, n=3). The
apparent increase in the number of tumor cells could not be simply
due to migration and homotypic aggregation of the injected tumor
cells because BrdU labeling showed widespread proliferation of the
tumor cells (Fig. 3A, inset). Similar results were obtained after
intraparenchymal injection of MDA-MB-231 cells (Fig. 3B). Thus,
vascular association or cooption does not rely on cells entering the
brain via extravasation from the blood supply and must be due
instead to preferential association of the tumor cells with the
vessels.
To further these findings, we directly observed tumor cells in vivo
using transcranial multiphoton and confocal imaging through a
cranial window in mice. This preparation allowed us to serially
revisit the same fields through the cranial window from 0 to 4 days
following intraparenchymal injection. Injected tumor cells were
seen to elongate upon blood vessels within 1 hour of injection (Fig.
S3). The majority of recently injected cells were spheroidal; after 2
d there was an obvious expansion of tumor cells in the same field
Vascular Soil for Metastasis
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(Figure 3D). The vascular pattern was not noticeably modified
after 2 days and there was no appearance of new vessels consistent
with tumor growth dependent upon preexisting vessels. However,
some vascular ectasia was noted and possibly associated with
greater tumor burden and/or a response to the tissue disruption
due to the injection (Fig. 3C, white arrowheads). These histological
and transcranial imaging studies were repeated using direct
injection of B16F10-GFP mouse melanoma cells with similar
results (Fig. S3). On the basis of these studies, we conclude that the
vascular association of tumor cells in brain colonies is not simply
due to the physical association of the tumor cell with the vessel
after extravasation, but is based upon preferential interactions with
the vessel.
Figure 1. Vascular cooption of cancer cells in brain metastasis formation. (A) Histological analysis of 4T1-GFP microcolonies demonstrating
intimate association with CD34+ capillaries (red) from 3 to 14 d after intracardiac injection of cells into syngeneic BALB/c mice. Insets are images of
vessels in the absence of the tumor cells/green channel. Arrow shows angiocentric invasion. All scale bars, 30 mm. (B) Quantification of tumor-
vascular association of 4T1-GFP at 3, 7, and 14 d (n=3–4 per timepoint). (C) Early brain microcolonies from human cell lines MDA-MB-231, MDA-MB-
231BR, and A7 and the murine melanoma K1735M2-GFP demonstrated similar vascular cooption (as indicated). Insets as in (A). Scale bar, 30 mm. (D)
Cross sectional tumor area measured at 3 and 7 d demonstrates rapid growth over this time (*P,0.05, t-test; n=256 colonies analyzed, 3–4 mice per
timepoint). (E) Immunofluorescence for BrdU (cyan) in a tumor colony at 7 d demonstrates a high proportion of proliferative perivascular cells within
the colony shown in the inset in green. Scale bar, 30 mm. (F) Projection image of a spontaneous 4T1-GFP brain micrometastasis demonstrates similar
features to colonies from the intracardiac model such as Glut-1 positive vessels (red) and angiocentric invasion (arrow). CD326 is an epithelial tumor
marker that only stains the tumor cells. Scale bar, 30 mm. Error bars represent s.d.
doi:10.1371/journal.pone.0005857.g001
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wall exterior
We sought to generate experimental situations in tissue culture
analogous to the intraparenchymal injections to characterize the
interaction of metastatic tumor cells with the vascular or neural
elements of the brain. First, we used an ex vivo assay with tumor
cells plated onto live, acutely isolated adult mouse brain slices [28].
All five of the murine and human tumor lines tested for
experimental brain metastasis in Fig. 1 were plated on live slices.
Each of these cell lines was found to preferentially elongate upon
the vasculature within 2 hours (Fig. 4A, 4B and S4). Tumor cells
not directly in contact with vessels did not spread (Fig. 4A and S4).
These results were directly verified with timelapse confocal
microscopy (Movie S1). Thus, we concluded that metastatic
carcinoma cells, when given equal access to live vascular and
neural substrates, interact preferentially with the vessels over the
neural parenchymal elements.
Based on morphological features of cells and microcolonies in
histological sections (Figs. 1 and 2) and the rapid cell spreading on
live slices observed above, we reasoned that there was likely an
active adhesive interaction between the metastatic tumor cells and
the exterior of blood vessels. To test the potential for tumor cell
adhesion to elements of the brain parenchyma, either vascular or
neural, we assayed adhesion of metastatic tumor cells plated on
thawed slide-mounted snap frozen brain sections. 4T1-GFP cells
were plated on normal murine brain and cultured for 2 h followed
by washing off non-adherent cells. Only a small minority of plated
cells adhered to the slices, however, 93% of these adherent cells
were in contact with vessels (Fig. 4C). To test the adhesion of
human tumor cells, we used the MDA-MB-231 breast carcinoma
line in a parallel assay with human brain sections. Similarly 85% of
the adherent human cells were associated with vessels (Fig. 4D and
S5). These results demonstrated that metastatic tumor cells adhere
to the brain parenchyma and that their preferred substrate is
vascular rather than neural. These studies complement the
observations in live slices that showed tumor cell spreading to be
associated with vascular, not parenchymal engagement.
Vascular cooption promotes CNS invasion of metastatic
cells
The preferential vessel adhesion and spreading of metastatic
tumor cells raised the possibility that invasion might also depend
upon the vasculature. To determine whether metastatic tumor
invasion required vessels or could occur via neural elements, we
modeled vascular invasion in vitro by plating 4T1-GFP spheroids
on live post-natal brain slices. After 3 to 7 days of co-culture,
Figure 2. Vascular cooption in human brain metastasis. (A) Human carcinomatous metastasis from lung primary tumor (third case in Table 1)
demonstrates vascular association. Right, high power view of hatched region. Scale bars, 0.5 mm (left), 120 mm (right). (B) Quantitation of vascular
association in human brain metastasis specimens of diverse primary origin from six patients (*P,0.001, t-test, n=3420 tumour profiles from 6
patients; Table 1). Error bars represent s.d.
doi:10.1371/journal.pone.0005857.g002



















Breast V-R 338 166 (49.1) 337 (99.7) no no no
Lung NSC micro/sol 430 406 (94.4) 419 (97.4) very rare very rare no
Lung NSC V-R 1000 684 (68.4) 985 (98.5) very rare rare no
? Breast, gyn V-R 1000 788 (78.8) 982 (98.2) very rare rare no
? Breast V-R 393 309 (78.6) 386 (98.2) very rare no no
Melanoma micro 264 256 (97.0) 256 (97.0) no rare no
*Clinical indices of angiogenesis.
Abbreviations: lung NSC, lung non-small cell carcinoma; gyn, gynecological carcinoma; micro, micrometastasis; sol, solitary metastases; V-R, Virchow-Robin space
invasion.
doi:10.1371/journal.pone.0005857.t001
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scaffolding (Fig. 5A and 5B). Spheroids that failed to contact
vessels showed little evidence of invasion into the brain slice
(Fig. 5A, right). The importance of vascular contact for invasion
was confirmed by measuring the depth of penetration into the
slices. The spheroids in contact with the vessels penetrated
significantly deeper into the brain slice than those without contact
(Fig. 5C). Thus, invasion of carcinoma cells in the brain
parenchyma preferentially involves vascular interactions.
Histological examination of the edges of the tumor masses from
microcolonies in the spontaneous, intracardiac injection, and
intraparenchymal models provided additional evidence for the
predominant association of invasion with vessels. The leading edge
from these tumors consisted of collective extensions/protrusions of
tumor cells growing along adjacent vasculature (Figs. 1A, 1F,
3A, 3B, and S3; arrows). Collective angiotropic invasion was
verified in the 4T1-GFP and B16F10-GFP models in vivo with
transcranial imaging (Fig. 3D and S3). Human brain metastasis
specimens were similarly examined for evidence of vascular
associated parenchymal invasion. In 80% (8 of 10) cases of well-
established solitary CNS breast cancer metastases, we could
identify at least one area at the tumor-brain interface consistent
with collective angiotropic invasion (Fig. 5D). Additionally,
vascular association was observed in specimens showing single
cell invasion (Fig. 5E). Finally, vascular-dependent invasion from
the Virchow-Robin spaces was observed identically in both the
mouse model and in carcinomatous human specimens (Fig. 5F).
Therefore, metastatic carcinoma cells have limited ability to
infiltrate neural substrates in vivo; instead, parenchymal invasion
occurs predominantly via the vasculature consistent with an
adhesive reliance on blood vessels.
Adhesion to VBM promotes growth of metastatic cells
The substrate for adhesion of carcinoma cells to brain vessels is
likely the vascular basement membrane (VBM) which is composed
predominantly of collagen type IV and laminins. Consistent with
this hypothesis, the spatial distribution of collagen types I and IV,
entactin fibronectin, laminin, and perlecan is limited to the
exterior of blood vessels in the brain parenchyma (Fig. S6). These
basement membrane proteins are known to promote anchorage-
dependent growth signaling of adherent cells and are widely used
to coat dishes for culture. To test the role of brain VBM in tumor
cell growth signaling we examined whether adhesion to VBM
components could potentiate metastatic cell proliferation in vitro in
the absence of serum. 4T1-GFP cells were plated on collagen I,
collagen IV, fibronectin, laminin, vitronectin, or BSA-coated
Figure 3. Vascular preference for CNS growth of carcinoma cells in vivo. 10
4 (A) 4T1-GFP or (B) MDA-MB-231 cells were injected directly into
the forebrain of mice. Representative coronal sections are shown after 4 d and demonstrate angiotropic growth (left; inset, BrdU from the main
tumor mass on an adjacent section). The right panels show a magnification of the hatched areas on the left further documenting the interaction of
the tumor cells with the vessels, in this case angiocentric invasion (arrows). Scale bars, 120 mm (left), 30 mm (right). (C) Serial transcranial confocal/
multiphoton imaging through a cranial window showed that colony expansion occurred along pre-existing vessels in vivo (n=5 mice). Day 0 (left),
Day 2 (right). Note dilatation of coopted vein compared to day 0 (white arrowheads). Scale bars, 240 mm. (D) Detail of hatched area in (C)
demonstrates tumor cells now present in previously uninvolved areas with extensive spreading on pre-existing vessels (arrows). Yellow arrowhead,
TRITC-dextran laden phagocytes. Scale bars, 30 mm.
doi:10.1371/journal.pone.0005857.g003
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measured at 48 h by BrdU incorporation ELISA. 4T1-GFP cells
demonstrated significantly increased BrdU incorporation on all
substrata compared to BSA (Fig. 6A). Consistent with the role of
ERK in anchorage-dependent signaling for cellular survival and
growth, this potentiation could be attenuated with incubation with
the highly specific MEK inhibitor, SL327. Similar results were
obtained with MDA-MB-231 and B16F10-GFP cells (Results not
shown). Therefore, individual components of VBM are sufficient
to support significant proliferation of metastatic tumor lines in the
absence of serum in vitro.
We sought to verify that anchorage-dependent growth signaling
from the VBM was a significant contribution to tumor growth in
vivo. In order to distinguish use of the VBM from those growth
signals and nutrients delivered directly from the bloodstream, we
tested whether non-perfused vessels could act as sites for vascular
cooption and tumor growth. Blood vessels were microdissected
from the brain surface and placed upon the site of intrapar-
enchmal tumor cell injection before implantation of a cranial
window. Serial transcranial imaging was then performed to
monitor tumor growth at 0, 2, and 4 days (Fig. 6B and results
not shown). Widespread angiotropic growth and invasion occurred
along the exterior of non-perfused vessels within just 2 d in 4 of 4
mice (Fig. 6C). This experiment suggests that adhesion to VBM of
non-perfused vessels can promote vascular cooption and early
growth of metastatic cells in the brain in vivo.
The mechanism of vascular cooption in the CNS
We have shown that the vascular association of tumor cells in
the CNS is based on adhesion to the VBM and that this
relationship supports establishment and progression of tumor
microcolonies independent of blood-born nutrients. Since cellular
adhesion to vascular basement membrane components requires
members of the integrin family of cellular adhesion receptors [29],
it is likely that vascular cooption and subsequent metastatic tumor
growth in the brain relies on identical mechanisms. As a corollary,
we found marked immunoreactivity for activated focal adhesion
kinase (pFAK-Y397), a major integrin signaling pathway, in 4T1-
GFP microcolonies in vivo (Fig. S7). To test this hypothesis directly
we investigated the effect of blocking integrin function on adhesion
Figure 4. Tumor cell interactions with CNS vessels. (A) 4T1-GFP cells were plated onto live adult murine brain slices and fixed after 2 h of co-
culture. 3-D reconstructions of hatched area (right panels) verify that the elongated tumor cell is spreading upon a vessel (arrows). Scale bar, 120 mm.
(B) Quantitation of vascular association on live brain slices with several mouse and human tumour lines demonstrates the vast majority of elongated
cells (82–90%) are attached to vessels (*P,0.05, Mann-Whitney U-test, n=294–546 cells per line, 2 independent experiments in duplicate). (C) 4T1-
GFP cells were plated onto slide-mounted tissue sections of murine brain for 2 h and non-adherent cells were rinsed off. Tumor cells preferentially
attached to vessels (arrows) rather than the neural elements (arrowhead). Graph, the location of the adherent cells was assessed (*P,0.01, Mann-
Whitney U-test, 2 independent experiments in triplicate). Scale bar, 60 mm. (D) Human MDA-MB-231 cells (arrows) were plated on slide-mounted
human brain sections. They similarly attached to vessels preferentially (arrows) over the neural parenchyma (arrowhead). (*P,0.01, Mann-Whitney U-
test, n=3 patient samples, 2 independent experiments in duplicate). Scale bar, 240 mm. All error bars represent s.d.
doi:10.1371/journal.pone.0005857.g004
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experiments on the human breast carcinoma line MDA-MB-231
because the integrin complement in this cell line has been well
characterized [30] and due to the wider array of effective anti-
integrin blocking antibodies available for human than for mouse.
First, we confirmed expression of various integrin subunits on
MDA-MB-231 microcolonies in vivo (Fig. S7) as previously
described in vitro [30]. We next tested integrin subunit blocking
antibodies on attachment to ECM in tissue culture. The anti-
b1integrin subunit antibody alone nearly completely blocked
adhesion of MDA-MB-231 cells to various types of ECM whereas
antibodies to any other single a or b subunit did not similarly block
adhesion (Fig. S7). Given the known functional redundancy in the
complement of b1 integrins and the dominant role for b1 signaling
in adhesion, migration and proliferation [31], this is not a
surprising result. Indeed, all cell lines used in this study expressed
high levels of b1 integrins (Fig. S7 and results not shown).
To test the importance of b1 integrins in brain metastasis, we
assayed tumor cell adhesion on a more physiologically-relevant
substrate using brain sections. MDA-MB-231 cells were preincu-
bated with either isotype-matched IgG1 control or anti-b1
activating or inhibiting antibodies prior to plating on adjacent
unfixed slide-mounted human brain sections (Fig. 7A). The tumor
cells when plated on brain sections had been noted to adhere
almost exclusively to vessels (Fig. 4C and 4D). Adhesion to vessels
was potentiated by anti-b1 integrin activating antibodies and
markedly attenuated by anti-b1 integrin blocking antibody (Fig. 7A
and 7B). Thus, adhesion of tumor cells to the VBM, and
consequently the process of vascular cooption, depends upon
tumor cell b1 integrins.
To investigate the relevance of the above findings in vivo we
asked whether blocking the b1 integrin subunit would affect
colony formation after intraparenchymal injection of tumor cells.
MDA-MB-231 cells were incubated with monoclonal antibodies
which block the function of the human, but not murine, b1
integrin subunit (Results not shown). Axial tumor area was
evaluated 4 d after the injection on histopathology (Fig. 7C). As
predicted, the brain colonies derived from cells treated with non-
Figure 5. Angiocentric invasion of parenchyma by brain metastases. (A) 4T1-GFP spheroids were plated onto live brain slices to assess
parenchymal invasion. 4T1-GFP spheroids invaded live brain slices upon the vascular scaffolding (left), but those spheroids contacting the brain
parenchyma in regions without vessels showed little morphological evidence of invasion (right). Scale bar, 60 mm. (B) The percent of invasive colonies
associated with vessels was significantly higher than those in contact only with the brain (*P,0.05, Mann-Whitney U-test, 2 independent
experiments). (C) The maximum depth of invasion by each spheroid into the brain slice was measured further confirming a vascular preference
(*P,0.001, Mann-Whitney U-test, 2 independent experiments). (D) Example of collective angiotropic invasion (arrow) from a human specimen of
brain metastasis from breast carcinoma. Asterisks, vessel lumens. Scale bar, 50 mm. (E) Example of single-cell angiocentric invasion (arrowhead) in the
brain from a human specimen of malignant melanoma brain metastasis. Arrows show endothelial cell nuclei. Scale bar, 20 mm. (F) Left, angiocentric
parenchymal invasion (arrow) was observed to occur from the Virchow-Robin spaces in human cases with carcinomatous CNS spread (lung
carcinoma, scale bar, 100 mm) as mirrored in the 4T1-GFP mouse model, right (scale bar, 120 mm). All error bars represent s.d.
doi:10.1371/journal.pone.0005857.g005
Vascular Soil for Metastasis
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5857blocking antibodies were significantly larger than those from the
cells treated with blocking antibodies (Fig. 7D). We verified the
antibody treatment itself was not toxic to these tumor cells after
culture in the absence of serum and ECM substrate (Results not
shown). Thus, cells treated with b1 integrin subunit blocking
antibodies largely failed to become established and grow in the
brain consistent with the inability to adhere to and utilize the
surrounding blood vessels.
Brain metastasis establishment requires b1 integrin-
mediated proliferation
The above results with function blocking antibodies identify an
important role for b1 integrins in metastatic tumor microcolony
establishment in the CNS. To further evaluate the effect of b1
integrins on colony formation, we analyzed CNS growth of ESb
murine lymphoma cells and of an engineered mutant in which the
b1 integrin subunit has been genetically eliminated (ESb-DKO)
[32]. Both ESb and ESb-DKO cells proliferate normally in
suspension in vitro under standard defined medium conditions ([32]
and Results not shown) and are not susceptible to anoikis. Similar
to the pathology seen in many human lymphomas, and in contrast
to that of carcinoma metastases, ESb cells diffusely invaded
through the parenchyma, but demonstrated superimposed peri-
vascular cuffing reminiscent of cooption (Fig. 8A). These cells
formed a rapidly growing lesion often measuring over a millimeter
in diameter in just 4 d. In contrast, the b1 integrin subunit
deficient ESb-DKO cells were significantly impaired in the ability
to grow and form an expanding lesion in the brain (Fig. 8B and
8C). ESb-DKO cells retained the capability for invasion deep into
the brain parenchyma confirming that the b1 integrin subunit is
not necessary for lymphoma invasion of the CNS [33] (Fig. 8B,
arrows). We noted a low baseline of BrdU+ profiles at the injection
site of mice and widespread invasion and BrdU-positive cells
throughout the cranial fascia and dermis overlying the injection
site in mice injected with ESb-DKO ruling out a proliferative
defect in the mutant line in vivo (Fig. S8) [32].
To verify that ESb cells interacted with the VBM in vivo,w e
analyzed tissue sections with immunohistochemistry against
activated focal adhesion kinase (pFAK-Y397) and activated
extracellular regulated kinase (pERK1/2). ESb cells were highly
immunoreactive for pFAK-Y397 confirming integrin-mediated
anchorage-dependent signaling (Fig. 8D). In contrast, ESb-DKO
cells demonstrated only background levels of immunoreactivity for
pFAK-Y397. ERK activity is downstream of FAK activation and
associated with survival and mitosis. We observed strong nuclear
and moderate cytoplasmic pERK1/2 immunoreactive ESb
lymphoma cells, but only weakly positive ESb-DKO cells in brain
colonies (Fig. 8E). In addition, ESb-colonized vessels demonstrated
frequent perivascular BrdU positive nuclei (Fig. 8F, inset).
Interestingly the majority of BrdU+ cells (67%) were found in
direct contact or within 10 mm of vessels (Fig. 8E). Therefore, ESb,
but not ESb-DKO, tumor cells in the brain were associated with
immunoreactivity for activated FAK and ERK as well as
perivascular BrdU consistent with proliferation via anchorage
Figure 6. Brain vascular basement membrane potentiates carcinoma growth. (A) Basement membrane components (as indicated)
potentiate incorporation of BrdU in 4T1-GFP cells in the absence of serum in vitro (*P,0.05, **P,0.001; ANOVA with Bonferroni Multiple Comparisons
Test, experiment in triplicate, 3 repeats). BrdU incorporation was attenuated by treatment with the selective MEK inhibitor SL327 (all post-drug
differences significant to P,0.01 except BSA). Error bars represent s.d. (B) After intraparenchymal injection of 4T1-GFP cells, several isolated
meningeal vessels were placed over the injected tumor cells. The 4T1-GFP cells grew on the basement membrane of these non-perfused microvessels
(outlined by arrows, left) in vivo. Growth was monitored with serial transcranial imaging; day 0 (left), day 2 (right). Scale bars, 240 mm. (C) Detail of
hatched region in (B) demonstrating growth upon non-perfused vessels (hatched white lines). Reconstructed Z-Y dimension image at the level of the
magenta line (right) demonstrates former lumens (asterisks) of the non-perfused vessels now surrounded by tumor cells. Scale bars, 30 mm (bottom).
doi:10.1371/journal.pone.0005857.g006
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on tumor cells mediates anchorage-dependent growth signaling
upon adhesion to the VBM of the neurovasculature and is essential
for the formation of metastatic brain colonies by ESb cells.
Further, the requirement for the b1 integrin subunit is indepen-
dent from protection from anoikis in this case.
Discussion
We have demonstrated that the primary soil for metastatic
tumor cell attachment and growth in the brain is vascular rather
than neural. This vascular cooption, or the utilization of pre-
existing vessels, has only been previously anecdotally reported as a
form of vascularization in experimental brain metastasis (Table
S1). Here, we have quantitatively demonstrated it to be the
predominant form of vessel use by tumor cells during early
experimental brain metastasis establishment and in human clinical
specimens reflecting early stages of the disease. We further show
the interaction relies on b1 integrin-mediated tumor cell adhesion
to the vascular basement membrane of blood vessels. These
findings exclude a requirement for de novo angiogenesis prior to
microcolony formation. They also contrast with the classical seed
and soil hypothesis for brain metastasis suggesting a neural
substrate and reliance upon neural-derived trophic factors for
growth. Importantly, they do not exclude vascular remodeling [24]
or contributions from the neural elements for later growth [34].
This work thus describes in detail a major mechanism of brain
metastasis formation in addition to identifying the mechanism of
vessel cooption in the brain for the first time.
The CNS parenchyma is largely devoid of non-vascular stromal
basement membrane components which are necessary for
epithelial and carcinoma cell adhesion and survival (Fig. S6).
Vascular cooption, therefore, supplies substrates for malignant
growth of non-neural carcinoma cells not otherwise widely
available in the neuropil. Proliferation by metastatic tumor cells
is highly potentiated upon adhesion to a basement membrane
substratum and is attenuated by inhibiting MEK in vitro.
Consistent with the experiments in tissue culture, during the early
stages of colony formation in vivo we found the vast majority of
micrometastases to be in direct contact with the VBM of existing
brain vessels and many of these cells were proliferating.
Resident neural stem cells tend to localize in perivascular
locations [35] and cells defined as brain tumor stem cells (BTSCs)
are found in a similar location [36,37]. Secreted paracrine growth
Figure 7. Adhesion to vascular basement membrane requires b1 integrin function. (A) MDA-MB-231 cells were tested for adhesion on
slide-mounted human brain slices. Cells were plated in the presence of the indicated antibody and then washed after 2 h. Micrographs demonstrate
adherent MDA-MB-231 cells (green) upon the same arteriole (red) in serial human brain sections under different treatment conditions (as indicated).
Scale bar, 120 mm. (B) Adhesion to vessels was significantly attenuated with anti-b1 function blocking antibodies (*P,0.001, Kruskal-Wallis test with
post-hoc Dunn’s multiple comparisons test, tissue from 2 patients run in duplicate and repeated) and potentiated with an activating anti-b1
antibody. (C) MDA-MB-231 cells (vimentin+, green) were treated with b1 integrin subunit blocking or non-blocking antibodies prior to
intraparenchymal injection in the brain of SCID mice. After 4 d, tumor colonies from animals in the non-blocking antibody condition (left panels)
demonstrated vascular associated growth and invasion in contrast to the blocking condition (right panels). Horizontal sections. Scale bar, 60 mm. (D)
Tumor cross sectional area was measured after 4 d growth with antibody treated cells showing significantly larger tumor area in the non-blocking
condition (*P,0.05, Mann-Whitney U-test, n=3–4 mice per treatment).
doi:10.1371/journal.pone.0005857.g007
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shown to stimulate the growth and survival of BTSCs. In contrast,
we demonstrated that slide-mounted brain sections (i.e., dead
tissue) still supplied the components needed for adhesion and
spreading by carcinoma cells. The requirement of metastatic
carcinoma cells for the vasculature in adhesion and invasion
during metastasis in the brain may be more analogous to the
requirement for VBM during development of pancreatic islets
[38]. Islet cells use b1 integrins to interface with the VBM and this
interaction is required for proliferation and endocrine function.
Nikolova et al. termed this basement membrane microenviron-
ment, a ‘‘vascular niche’’ [38,39]. Similarly vascular mural cells
require the b1 integrin subunit for proper adhesion to vessels and
for maintaining vessel stability [40]. In an analogous fashion,
carcinoma cells, then, appear to hijack the brain’s VBM for
essential functions during brain metastasis. Interestingly, inhibiting
angiogenesis in circumscribed, well-established CNS melanoma
metastases causes reversion to growth by vascular cooption [19].
This suggests a continuum for vessel utilization by tumor cells
which may represent a viable target for therapeutic exploitation.
The interaction between the tumor cells and the vessels relies on
b1 integrin-mediated tumor cell adhesion to the vascular basement
membrane of blood vessels. This interaction is sufficient to
promote immediate proliferation and micrometastasis establish-
ment of tumor lines in the brain. This angiotropic mechanism was
universal to both carcinomas (anchorage-dependent cells) and
lymphomas (anchorage-dispensible cells) in the CNS. b1 integrins
play a dominant role in many facets of normal cell biology and
have been implicated in cancer initiation, progression, and
metastasis [30–32,41–44]. There are at least 10 b1 integrin
heterodimers which serve as variably promiscuous adhesive
receptors to diverse ligands such as the collagens and laminins.
Nonetheless our data suggest that antagonism of the b1 integrin
subunit alone might be useful in therapeutic strategies for brain
metastases. Indeed, Park et al [42] found that inhibitory anti-b1
integrin subunit antibodies induced apoptosis in breast carcinoma
cells grown in three dimensional culture, but not in cells grown in
monolayers. Treating mice bearing breast cancer xenografts from
those cell lines with the same antibody led to decreased tumor
volume. In addition to the apoptotic mechanism described in vitro,
inhibition of vascular cooption may have also attenuated growth.
In an alternative strategy to evaluate the role of b1 integrins,
tumors were analyzed in the MMTV/PyMT transgenic model of
breast cancer [43]. Conditional deletion of b1 integrin after
induction of tumorigenesis resulted in impairment of FAK
phosphorylation and proliferation consistent with a reliance on
anchorage-dependent signaling for tumor growth. Although the
presence of the b1 integrin subunit is mandatory for embryonic
development, chronic systemic anti-b1 antibody therapy did not
result in overt toxicities in adult mice [42]. Further research into
the regulation of b1 integrin regulation, function and downstream
signaling may yield clinically useful applications for metastatic
disease in cancer patients [31,45,46].
Materials and Methods
Ethics statement
Animal procedures were performed under UK Home Office
licensing and ethics committee approval from the Clinical
Medicine Ethical Review Committee at the University of Oxford.
Human tissue was retrieved from the Thomas Willis Oxford Brain
Collection with prior written informed consent and final approval
from the local research ethics committee (reference 06/Q1604/
141).
In vivo experiments
All animal procedures were approved by the UK Home Office.
Experimental brain metastases were established by intracardiac
injection of 10
5 tumor cells [11]. Alternatively, direct intraparen-
chymal injection of 5610
3 to 10
4 cells was performed into the
striatum or hippocampus with a stereotaxic apparatus (Bench-
mark, MyNeurolab.com). MRI imaging was performed with a 7-
Tesla horizontal bore magnet with a Varian Inova spectrometer
(Varian) between 2 and 14 d post tumor inoculation. Transcranial
imaging was performed up to 3 times via cranial window with a
Leica TCS-SP2 AOBS confocal microscope and a Spectra-Physics
MaiTai Ti-Sapphire pulsed laser.
In vitro experiments
VBM adhesion and proliferation assays were performed with
10 mg/ml ECM components or BSA (control). Adhesion was
tested after 2 h and proliferation after 48 h. Adhesion to brain
sections was evaluated after 2 h [28]. Non-adherent cells were
rinsed off in three rinses of PBS on a shaker set. Live brain slice
assays were performed acutely for 2 hours or 3 to 7 d for long-term
culture as described in Text S1.
Human specimens
Clinical neuropathology specimens were obtained with ethics
committee approval from routine neurosurgical or autopsy
procedures and processed for routine immunohistochemistry and
analyzed as described in Text S1.
Integrin inhibition studies
Inhibitory monoclonal antibodies against integrin subunits and
isotype control antibodies were used at 5 to 20 mg/ml.
Histological analysis
Experimental tissues were collected under terminal anesthesia
after transcardiac perfusion with saline and 4% paraformaldehyde
or organs were freshly isolated and snap frozen or immersion
Figure 8. b1 integrin is required for angiocentric growth of tumor cells in the CNS in vivo.( A) Representative montage demonstrates
tumor growth and invasion of ESb cells (CD45+, green) from the point of initial injection (asterisk). Despite the ability of single cells to migrate
through the brain parenchyma there was a clear preference for growth upon vessels (hatched areas, lower panels). Inset, lower left demonstrates
BrdU+ (cyan) perivascular ESb cells. Scale bar, 500 mm (montage), 60 mm (bottom micrographs). FFX, fimbria/fornix bundle. (B) in vivo growth of ESb-
DKO murine lymphoma cells (b1 integrin null) is highly impaired relative to ESb cells (A). Long-distance migration of single cells is not affected
(arrowheads). Scale bar, 240 mm. (C) Tumor area was nearly 22 times greater in the ESb compared to the ESb-DKO line at 4 d (*p,0.01; error bars
represent s.d.; n=3–4). (D) Immunohistochemistry for activated FAK (pFAK-Y397) demonstrates strong staining in perivascular wild-type ESb cells
(left) but little staining in ESb-DKO cells (right). Scale bar, 60 mm. Asterisk, injection site. (E) Immunohistochemistry for activated ERK (pERK1/2) shows
strong nuclear staining and moderate cytoplasmic staining of perivascular ESb lymphoma cells (left) but not in ESb-DKO cells (right). Scale bars,
240 mm (top) and 30 mm (bottom). (F) Histogram demonstrating perivascular distribution of BrdU+ profiles in animals injected with ESb cells (cyan).
The majority of BrdU+ profiles are within 1 cell diameter of vessels (mean 6 s.d. distance: 7.569.4 mm).
doi:10.1371/journal.pone.0005857.g008
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S1 in 15-30 mm cryostat sections.
Statistical analyses
Data were compiled in MS Excel and data analyzed with Excel
or Graph Pad InStat 3. Pairwise comparisons were made with an
unpaired t-test or the Mann-Whitney u-test as appropriate.
Evaluation of variance in data groups was performed with
ANOVA or the Kruskal-Wallis test as appropriate. If significance
was detected post-hoc comparisons were made with an appropri-
ate post-hoc test. A p,0.05 was considered statistically significant.
For detailed methodology please see Text S1.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0005857.s001 (0.05 MB
DOC)
Figure S1 Brain seeking MDA231BR line requires vascular
cooption for CNS growth. (A) Intracardiac injection of metastatic
human breast carcinoma MDA-MB-231 or the brain seeking
subclone, MDA231BR, results in tumour growth on existing brain
vessels at 7–14 d. Vascular association of colonies for either cell
line was.97% (left) (B) despite a greater number of brain colonies
formed after injection of MDA231BR than after the parental line
(middle, *P,0.05, Mann-Whitney U-test). (C) Tumour area from
each subclone was also equivalent (right). These results further
support the hypothesis that interactions with existing vessels are
necessary for initial growth of brain metastases. All error bars
represent s.d. (n=3–4 mice per cell line).
Found at: doi:10.1371/journal.pone.0005857.s002 (0.06 MB TIF)
Figure S2 Experimental brain micrometastases coopt and grow
upon pre-existing vessels. (A) Representative images of tumor-
associated cortical vessels or control hemisphere visualized by
Glut-1 immunoreactivity (red), a biomarker for an intact blood-
brain barrier (BBB). Inset shows the vascular associated tumor cells
(green) superimposed on the vasculature. Scale bar, 120 mm. (B)
Quantitation demonstrates significantly lower vascular density in
regions with growing brain metastases compared to corresponding
fields in control brains. (*P,0.05, t-test; n=3 per group). Error
bars represent s.d. (C) High resolution T2-weighted and
gadolinium-dTPA enhanced T1-weighted MRI largely failed to
reveal experimental brain microcolonies at timepoints between 7
and 14 d after intracardiac inoculation (n=5). This is consistent
with the lack of blood brain barrier (BBB) leakage as would be
expected from new tumour vessels. Yellow arrowhead, high
intensity signal in sagittal sinus serves as positive control for
gadolinium enhancement. Bottom, representative brain section
(fluorescent montage) at +4.0 Bregma demonstrates numerous
tumour microcolonies (white arrowheads) which were not detected
by MRI. Scale bar, 1 mm (montage). (D) BBB integrity was further
verified with enzymatic immunofluorescence for mouse IgG on
adjacent sections. Middle, high power micrograph of boxed area
in (C) displays a 4T1-GFP microcolony with no detectible frank
BBB disruption. Positive and negative controls as indicated. High
concentration of IgG in microglia and vessels as previously
described [47]. Arrows, microglia; arrowheads, vessels. Scale bar,
40 mm (micrograph).
Found at: doi:10.1371/journal.pone.0005857.s003 (1.75 MB TIF)
Figure S3 Active vascular preference of carcinoma cells in the
brain in vivo. (A) 1 h after intraparenchymal injection of 4T1-GFP
cells into BALB/c mice, cells were visualized through a cranial
window. Tumor cells could be seen spreading along the pre-
existing vessels (arrow). Scale bar, 15 mm. (B) B16F10-GFP murine
metastatic melanoma cells associate with preexisting vessels in the
CNS after intraparenchymal injection. Left, histological section at
4 d. Right, imaging vascular invasive cells through cranial window
in a live anesthetized mouse. Arrows, angiocentric invasion. Scale
bars, 30 mm.
Found at: doi:10.1371/journal.pone.0005857.s004 (0.86 MB TIF)
Figure S4 Carcinoma cell spreading on vessels in live brain
slices. (A) Distribution of cell morphologies after co-culture with
acutely isolated living brain slices. 56103 tumour cells were plated
on each brain slice and analysed for morphology after 2 hours.
Elongated cells represented a small subset of cells in all tumour
lines. (B) All cells were scored in regard to contact with blood
vessels and graphed according to morphology. Indeed, upwards of
90% of elongated cells for all 5 cell lines were in contact with blood
vessels. There were significantly more vascular associated
elongated cells compared to round cells associated with vessels
(p,0.01 for all cell lines, Kruskal-Wallis test with post-hoc Dunn’s
multiple comparisons test, error bars represent s.d.). This suggests
vascular contact is causal in the ability for the cells to spread out or
elongate on brain slices. (C-F), Representative fields of the various
cell lines (as indicated) plated upon live brain slices demonstrating
vascular preference of elongated cells. Right panels (C-F) represent
high power views of hatched areas for greater detail. Arrows,
elongated vascular associated cells. MDA-MB-231, MDA231BR,
and A7 cells are identified by vital staining with CMRA prior to
co-culture (red). Scale bars, 120 mm (C, D, and F), 60 mm (E).
Found at: doi:10.1371/journal.pone.0005857.s005 (0.87 MB TIF)
Figure S5 Carcinoma cells preferentially adhere to brain vessels
in situ. (A) Adherent MDA-MB-231 cells appeared to prefer cross-
sectional arteries and arterioles as a substrate (see Fig. 4D) in
human tissue and were found to adhere especially to the muscular
layer of the vessel wall. This layer, found between the media
intima and adventitia, possesses a fine reticular meshwork of
vascular basement membrane proteins which likely serves as the
primary adhesion substrate (right panels; scale bars, 60 mm, left;
15 mm, right.). The seeming arterial preference may be due to the
larger exposed area of basement membrane of arterioles compared
to (B) veins and (C) capillaries. White arrow, media intima; yellow
arrow, media adventitia. Scale bars (B and C), 120 mm.
Found at: doi:10.1371/journal.pone.0005857.s006 (2.17 MB TIF)
Figure S6 Basement membrane proteins are limited to brain
blood vessels (A) Distribution of collagen type I, collagen type IV,
entactin, fibronectin, laminin, and perlecan in the normal murine
brain was evaluated with immunofluorescence on horizontal
sections. Micrographs were acquired in the cortex. The VBM
components were largely limited to the vasculature as demon-
strated by co-localisation with the endothelial cell markers Glut-1
or CD34 (green). White arrowhead, collagen type I expression in
pia mater. Scale bar, 60 mm. (B) In contrast, immunostaining of
normal mouse visceral organs (as indicated) produced vascular and
extensive extravascular immunoreactivity for laminin. Scale bar,
60 mm.
Found at: doi:10.1371/journal.pone.0005857.s007 (2.84 MB TIF)
Figure S7 Integrins mediate adhesion to brain vessels. (A)
Murine mammary carcinoma 4T1-GFP brain microcolonies are
immunoreactive to activated focal adhesion kinase (pFAK-Y397)
suggestive of integrin-mediated downstream signaling. Scale bars,
60 mm (left) and 30 mm (right). (B) Expression of integrin subunits
previously reported to be expressed in MDA-MB-231 cells in vitro
[30] was verified in experimental brain metastases in vivo 7 d after
intracardiac injection. All eight subunits (a6, not shown) were
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cence using human-specific monoclonal antibodies. Scale bar,
15 mm. (C) MDA-MB-231 breast carcinoma cells were tested for
adhesion to human placental collagen type IV or laminin in the
presence of the indicated blocking antibodies (* p.0.01, ANOVA
with post-hoc Dunnet multiple comparisons test, performed in
quadruplicate and repeated). (D) The effect of blocking antibodies
to human b1o rb3 integrin subunits, of control IgG, or of
activating b1 integrin subunit antibody was tested on adhesion of
MDA-MB-231 human breast carcinoma cells to mouse EHS
collagen type IV and laminin (p.*0.01 both comparisons,
ANOVA with post-hoc Dunnet multiple comparisons test,
performed in triplicate or quadruplicate and repeated). These
experiments identified the b1 subunit to be obligatory for MDA-
MB-231 breast carcinoma adhesion to murine EHS collagen type
IV and laminin and human HP collagen type IV. (E) Western blot
for the carboxy terminus of the b1 integrin subunit reveals
expression in all tumor cell lines used in this study analyzed (other
lines not shown). Numerous glycosylated isoforms [45] as well as
species-specific variants can be appreciated. b actin served as
loading control. (F) b1 integrin subunit immunofluorescence on
the cell membrane in both 4T1-GFP and MDA-MB-231 (as
indicated) cells plated in collagen type IV coated wells.
Immunoreactivity was also seen particularly distally in cell
processes of MDA-MB-231 cells (arrows). Scale bar, 30 mm
(top), 10 mm (bottom).
Found at: doi:10.1371/journal.pone.0005857.s008 (0.67 MB TIF)
Figure S8 b1 integrin null ESb-DKO cells are not generally
growth defective in vivo. (A) BrdU immunohistochemistry (cyan)
of tissue sections from DBA/2 mice 4 d after intraparenchymal
injection of ESb-DKO cells (green, inset) demonstrates a low
baseline of proliferation (horizontal brain section). Scale bar,
30 mm. (B) ESb-DKO cells are able to invade, grow, and
proliferate (inset) within several layers of the scalp over the
injection site (arrow, hair follicle; coronal brain section). Scale bar,
240 mm.
Found at: doi:10.1371/journal.pone.0005857.s009 (0.43 MB TIF)
Text S1 Detailed Experimental Procedures
Found at: doi:10.1371/journal.pone.0005857.s010 (0.14 MB
DOC)
Movie S1 Tumor cell spreading on live brain slices requires
vascular contact. Timelapse confocal microscopy of A7 human
malignant melanoma cells (red) plated onto a live SCID brain slice
demonstrates a vascular associated cell elongating (center) upon a
large exposed vessel (green) over the course of 30 minutes.
Vasculature vitally stained with GS-IB4 lectin (Alexa 488). Z-
stacks were captured every 3 m and 2D z-projections compiled
with ImageJ.
Found at: doi:10.1371/journal.pone.0005857.s011 (0.05 MB
MOV)
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